SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
NKTR

Nektar Therapeutics (NASDAQ:NKTR)

US · Delayed Price · Currency is USD
Also listed: 0UNL.LHealthcare · Biotechnology
$30.20-$2.34 (-7.19%)
 
Market cap
$866M
Insider Score
Health Score
Analyst consensus
Listed since
May 3, 1994
Website
Market Cap$866.38M-48.5%
Revenue (ttm)$52.19M-16.6%
Net Income-$177.26M-46.8%
EPS-$6.46+18.5%
Shares Out28.69M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,017,708
Open$31.66
Previous Close$32.54
Day's Range$30.13 - $32.35
52-Week Range$30.13 - $109.00
Beta1.15
AnalystsBuy
Price Target$107.20(+254.97%)
Earnings DateMar 11, 2027

About NKTR

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Address
455 Mission Bay Boulevard South, San Francisco, CA, 94158, US
Market Cap
866 million
Employees
63
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.46M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy1 Hold0 SellAvg target $128.29 (+324.8%)

3 firms rating NKTR in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From NKTR’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-7.19%
5 Days
-18.05%
1 Month
-21.86%
6 Months
-54.66%
1 Year
-48.50%

$NKTR stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of NKTR by members of U.S. Congress

Josh GottheimerHouse / DSale$1.00K – $15.00KJun 21, 2018
Josh GottheimerHouse / DPurchase$1.00K – $15.00KJun 6, 2018

Recently reported changes in NKTR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by NKTR's directors and management

Net Shares Purchased by Insiders−40k−20k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

NKTR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

NKTR Revenue by Segment

$41.06MTotal
Other operating costs$19.57M47.67%
Employee costs$18.88M45.97%
Facilities costs$2.61M6.36%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New NKTR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to NKTR from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in NKTR

VTIVanguard Morningstar Total Stock Market ETF$33.13M
XBIState Street SPDR S&P Biotech ETF$32.53M
IWMiShares Russell 2000 ETF$29.39M
VXFVanguard Extended Market ETF$15.12M
IWOiShares Russell 2000 Growth ETF$9.46M
VTWOVanguard Russell 2000 ETF$7.88M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from NKTR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
35

News check: Q3 earnings miss on revenue, analyst price target cut, offset partially by clinical trial progress and narrowing losses.

Recent Insider Activity

Buys
0
Sells
18
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.37%
SPITF/m Emerald Special Situations ETF1.69%
LFSCF/M Emerald Life Sciences Innovation ETF1.58%
SBIOALPS Medical Breakthroughs ETF0.83%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.51%
BBCVirtus Biotech Clinical Trials ETF0.48%
XBIState Street SPDR S&P Biotech ETF0.37%
QQQSInvesco NASDAQ Future Gen 200 ETF0.30%
DMRMDeltaShares S&P 400 Managed Risk ETF0.13%
VTWGVanguard Russell 2000 Growth ETF0.12%
FTKIFirst Trust Small Cap BuyWrite Income ETF0.09%
JKLiShares Morningstar Small-Cap Value ETF0.09%

Weight is the stock’s share of each fund’s holdings.